NCT00856440

Brief Summary

Periodic screening for colon cancer has become the standard of care in individuals over the age of 50. In this context, it is generally accepted that colonoscopy is the most sensitive modality for the detection of colon cancer and/or pre malignant colon pathology. As currently performed, however, colonoscopy requires that stool be eliminated from the colon before the examination. If stool remains in the colon, visualization of the bowel will be partially or completely impaired and limits the effectiveness of the screening. A number of methods are employed for purging the bowel of waste material but they generally involve either administration of a lavage (like a flush) solution (such as Colyte or Golytely) or of an osmotic laxative (such as sodium phosphate or magnesium citrate). Neither of these approaches is uniformly effective in all individuals and neither is without potential complications, especially on the kidneys. It is the intent of the proposed research to study the relative efficacy and safety of these preparations in both able-bodied individuals as well as people with spinal cord injury. To this end, we will randomize these groups to a lavage solution, a laxative or a combination of the two prior to a routine, clinically indicated colonoscopy. The quality of the preparation will be directly assessed during the colonoscopy and the effect of these preparations on kidney function will be determined. We suspect that when it comes to preparation for colonoscopy, one shoe does not fit all sizes. The proposed research should allow us to determine which form of preparation is least harmful while achieving optimal effectiveness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
330

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2006

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 2, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 5, 2009

Completed
Last Updated

July 16, 2010

Status Verified

July 1, 2010

Enrollment Period

2.5 years

First QC Date

March 2, 2009

Last Update Submit

July 15, 2010

Conditions

Keywords

SCI

Outcome Measures

Primary Outcomes (1)

  • Renal Function (GFR, creatinine clearance)

    <30 days

Secondary Outcomes (1)

  • Quality of bowel preparation (Ottawa Score)

    <30 days

Study Arms (2)

1

SCI

Drug: Fleets Oral Sodium Phosphate Solution (OSPS)Drug: ColyteDrug: Dual (OSPS & Colyte)

2

Able-bodied

Drug: Fleets Oral Sodium Phosphate Solution (OSPS)Drug: ColyteDrug: Dual (OSPS & Colyte)

Interventions

Osmotic preparation for colonoscopy

Also known as: Phospho Soda
12
ColyteDRUG

Lavage preparation for colonoscopy

Also known as: Golytely
12

Combined, two-day preparation utilizing both preparations

12

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Veterans, SCI and able-bodied

You may qualify if:

  • \. Patients already clinically indicated for colonoscopy examination

You may not qualify if:

  • Patients who are not a candidate for elective colonoscopy (i.e. those with recent myocardial infarction, terminal illness, etc.)
  • Patients who have a contraindication for Colyte (i.e. those with colonic obstruction, etc.)
  • Patients who have a contraindication for Fleet OSPS (i.e. those with poor renal function, class 2 or greater symptomatic heart failure, etc.)
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Medical Center, Bronx

The Bronx, New York, 10468, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and urine samples

MeSH Terms

Conditions

Spinal Cord Injuries

Interventions

Golytely

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and Injuries

Study Officials

  • Mark A. Korsten, MD

    VA Medical Center, Bronx

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
FED

Study Record Dates

First Submitted

March 2, 2009

First Posted

March 5, 2009

Study Start

June 1, 2006

Primary Completion

December 1, 2008

Study Completion

December 1, 2008

Last Updated

July 16, 2010

Record last verified: 2010-07

Locations